* Apellis Pharmaceuticals Inc reported a quarterly adjusted loss of 46 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.17. The mean expectation of twenty analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -43 cents to -17 cents per share.
* Revenue rose 78.3% to $196.83 million from a year ago; analysts expected $200.35 million.
* Apellis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 46 cents.
* The company reported a quarterly loss of $57.45 million.
* Apellis Pharmaceuticals Inc shares had fallen by 2.7% this quarter and lost 53.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 23.9% in the last three months.
* In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is 52.00 This summary was machine generated from LSEG data November 6 at 04:54 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.30 -0.46 Missed
Jun. 30 2024 -0.32 -0.28 Beat
Mar. 31 2024 -0.47 -0.42 Beat
Dec. 31 2023 -0.69 -0.73 Missed
Comments